P784: CYCLOSPORINE WITH THROMBOPOIETIN RECEPTOR AGONIST IN THE TREATMENT OF APLASTIC ANEMIA WITH OR WITHOUT ANTI-THYMOCYTE IMMUNOGLOBULIN:A MULTICENTER REAL WORLD RETROSPECTIVE STUDY
Main Authors: | Miao Chen, Bing Han |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-08-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000970040.32760.b3 |
Similar Items
-
An investigation of long-term outcome of rabbit anti-thymocyte globulin and cyclosporine therapy for pediatric severe aplastic anemia
by: Lixian Chang, et al.
Published: (2023-07-01) -
High- vs regular-dose recombinant human thrombopoietin plus cyclosporine A in patients with newly diagnosed non-severe aplastic anemia: a retrospective cohort study
by: Yuan Yang, et al.
Published: (2024-12-01) -
Aplastic anemia with thrombopoietin gene mutation successfully treated with romiplostim monotherapy
by: Niranjan Gurunath Hegde, et al.
Published: (2023-01-01) -
Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory/relapsed/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial
by: Ziqi Wan, et al.
Published: (2023-12-01) -
Adding cyclosporin A to eltrombopag for aplastic anemia secondary to chemotherapy for solid cancers
by: Ziqi Wan, et al.
Published: (2023-05-01)